<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34159342</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>medRxiv : the preprint server for health sciences</Title>
          <ISOAbbreviation>medRxiv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Molnupiravir, an Oral Antiviral Treatment for COVID-19.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">2021.06.17.21258639</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1101/2021.06.17.21258639</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19 ( ClinicalTrials.gov NCT04405570 ).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days. Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fischer</LastName>
            <ForeName>William</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eron</LastName>
            <ForeName>Joseph J</ForeName>
            <Initials>JJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holman</LastName>
            <ForeName>Wayne</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Myron S</ForeName>
            <Initials>MS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Szewczyk</LastName>
            <ForeName>Laura J</ForeName>
            <Initials>LJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sheahan</LastName>
            <ForeName>Timothy P</ForeName>
            <Initials>TP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baric</LastName>
            <ForeName>Ralph</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mollan</LastName>
            <ForeName>Katie R</ForeName>
            <Initials>KR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wolfe</LastName>
            <ForeName>Cameron R</ForeName>
            <Initials>CR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duke</LastName>
            <ForeName>Elizabeth R</ForeName>
            <Initials>ER</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Azizad</LastName>
            <ForeName>Masoud M</ForeName>
            <Initials>MM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Borroto-Esoda</LastName>
            <ForeName>Katyna</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wohl</LastName>
            <ForeName>David A</ForeName>
            <Initials>DA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Loftis</LastName>
            <ForeName>Amy James</ForeName>
            <Initials>AJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alabanza</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lipansky</LastName>
            <ForeName>Felicia</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Painter</LastName>
            <ForeName>Wendy P</ForeName>
            <Initials>WP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT04405570</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D000076942">Preprint</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>medRxiv</MedlineTA>
        <NlmUniqueID>101767986</NlmUniqueID>
      </MedlineJournalInfo>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="UpdateIn">
          <RefSource>Sci Transl Med. 2022 Jan 19;14(628):eabl7430</RefSource>
          <PMID Version="1">34941423</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>7</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34159342</ArticleId>
        <ArticleId IdType="pmc">PMC8219109</ArticleId>
        <ArticleId IdType="doi">10.1101/2021.06.17.21258639</ArticleId>
        <ArticleId IdType="pii">2021.06.17.21258639</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
